Guardant Health is a biotechnology company that specializes in the development and commercialization of liquid biopsy technologies for cancer detection and treatment monitoring. The company was founded in 2012 and is headquartered in Redwood City, California.

Guardant Health’s liquid biopsy technology enables the detection of cancer through the analysis of cell-free DNA (cfDNA) circulating in the bloodstream. The company’s flagship product, Guardant360, is a non-invasive blood test that analyzes over 70 genes to identify specific mutations that are commonly found in cancer cells. The test can be used to help guide treatment decisions, monitor treatment response, and identify potential drug resistance.

One of the key strengths of Guardant Health is its focus on precision oncology. The company’s liquid biopsy technology enables the identification of specific genetic mutations in cancer cells, which can help oncologists tailor treatment plans to each patient’s individual needs. The technology also allows for more frequent monitoring of treatment response, which can help identify potential issues earlier and improve patient outcomes.

Guardant Health’s liquid biopsy technology is used by healthcare providers and researchers around the world to improve the diagnosis and treatment of cancer. The company has received numerous awards and accolades for its innovative products and services, and is recognized as a leader in the liquid biopsy space.

Today, Guardant Health is a rapidly growing company with a global presence, and is committed to improving cancer care through innovation and technology. The company is dedicated to improving patient outcomes and quality of life, and is driven by a passion for transforming the way cancer is diagnosed and treated.